$SRNE
Sorrento Therapeutics Inc Stock $srne

$srne Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000095017022003472 Filed on March 11, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021
Revenue	$13.08M	$12.06M	$52.90M
YoY Change	13.65%	2.63%	32.31%
Cost Of Revenue	$3.137M	$3.387M	$13.03M
YoY Change	20.65%	25.44%	31.63%
Gross Profit	$9.939M	$8.675M	$39.87M
YoY Change	11.67%	-4.67%	32.91%
Gross Profit Margin	76.01%	71.92%	75.37%
Selling, General & Admin	$54.58M	$48.49M	$196.9M
YoY Change	32.48%	99.54%	69.41%
% of Gross Profit	549.15%	558.95%	493.71%
Research & Development	$59.74M	$49.45M	$206.9M
YoY Change	60.15%	54.51%	85.85%
% of Gross Profit	601.02%	570.01%	518.95%
Depreciation & Amortization	$2.859M	$3.547M	$8.300M
YoY Change	28.78%	12.96%	18.57%
% of Gross Profit	28.77%	40.89%	20.82%
Operating Expenses	$124.5M	$49.45M	$206.9M
YoY Change	56.86%	54.51%	85.85%
Operating Profit	-$114.6M	-$101.4M	-$401.5M
YoY Change	62.57%	22.0%	64.18%
Interest Expense	-$35.46M	$2.900M	$10.22M
YoY Change	1318.36%	13.19%	-49.28%
% of Operating Profit
Other Income/Expense, Net	-$28.00M		-$28.00M
YoY Change
Pretax Income	-$178.1M	-$119.8M	-$462.7M
YoY Change	143.6%	38.63%	46.21%
Income Tax	-$33.06M	$400.0K	-$33.52M
% Of Pretax Income
Net Earnings	-$144.4M	-$119.8M	-$428.3M
YoY Change	101.97%	42.58%	43.51%
Net Earnings / Revenue	-1104.44%	-993.23%	-809.63%
Basic Earnings Per Share	-$0.47	-$0.40	-$1.45
Diluted Earnings Per Share	-$0.47	-$0.40	-$1.45
COMMON SHARES
Basic Shares Outstanding	308.9M	299.3M	294.8M
Diluted Shares Outstanding	308.9M	299.3M	294.8M

Balance Sheet

Concept	2021 Q4	2021 Q3	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$126.9M	$162.7M	$126.9M
YoY Change	124.57%	116.32%	124.57%
Cash & Equivalents	$36.67M	$39.74M	$36.67M
Short-Term Investments	$90.22M	$122.9M	$90.22M
Other Short-Term Assets	$7.482M	$3.974M	$19.29M
YoY Change	101.07%	-71.41%	55.53%
Inventory	$8.106M	$5.427M	$8.106M
Prepaid Expenses	$11.80M	$12.20M
Receivables	$18.72M	$16.45M	$18.72M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$173.0M	$200.7M	$173.0M
YoY Change	100.6%	89.36%	100.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$41.33M	$45.75M	$126.5M
YoY Change	29.7%	-38.43%	71.17%
Goodwill	$79.53M	$52.90M
YoY Change	82.59%	38.12%
Intangibles	$259.7M	$321.0M
YoY Change	252.5%	301.38%
Long-Term Investments	$51.27M	$51.12M	$51.27M
YoY Change	-80.0%	-80.06%	-80.0%
Other Assets	$4.830M	$4.664M	$4.830M
YoY Change	135.72%	119.48%	141.5%
Total Long-Term Assets	$521.8M	$552.1M	$521.8M
YoY Change	16.07%	11.29%	16.07%
TOTAL ASSETS
Total Short-Term Assets	$173.0M	$200.7M	$173.0M
Total Long-Term Assets	$521.8M	$552.1M	$521.8M
Total Assets	$694.8M	$752.8M	$694.8M
YoY Change	29.67%	25.03%	29.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$27.41M	$27.84M	$27.41M
YoY Change	10.96%	21.84%	10.99%
Accrued Expenses	$37.98M	$23.58M	$71.02M
YoY Change	97.81%	-4.02%	62.51%
Deferred Revenue	$1.108M	$2.284M
YoY Change	-75.3%	-45.23%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$31.98M	$27.49M	$31.98M
YoY Change	37.8%	48.34%	37.84%
Total Short-Term Liabilities	$139.5M	$175.2M	$139.5M
YoY Change	44.54%	90.16%	44.51%
LONG-TERM LIABILITIES
Long-Term Debt	$110.6M	$83.50M	$110.6M
YoY Change	19.91%	-44.14%	19.86%
Other Long-Term Liabilities	$1.761M	$1.761M	$364.2M
YoY Change		220.77%	82.64%
Total Long-Term Liabilities	$112.4M	$85.26M	$474.8M
YoY Change	21.82%	-43.17%	62.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$139.5M	$175.2M	$139.5M
Total Long-Term Liabilities	$112.4M	$85.26M	$474.8M
Total Liabilities	$616.7M	$621.5M	$616.1M
YoY Change	56.09%	36.05%	66.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.387B	-$1.242B
YoY Change	44.7%	40.08%
Common Stock	$1.514B	$1.422B
YoY Change	29.12%	24.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$49.46M	$49.46M
YoY Change	0.0%	0.0%
Treasury Stock Shares	$7.568M	$7.568M
Shareholders Equity	$78.75M	$131.5M	$78.75M
YoY Change
Total Liabilities & Shareholders Equity	$694.8M	$752.8M	$694.8M
YoY Change	29.67%	25.03%	29.68%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021
OPERATING ACTIVITIES
Net Income	-$144.4M	-$119.8M	-$428.3M
YoY Change	101.97%	42.58%	43.51%
Depreciation, Depletion And Amortization	$2.859M	$3.547M	$8.300M
YoY Change	28.78%	12.96%	18.57%
Cash From Operating Activities	-$72.14M	-$83.11M	-$281.8M
YoY Change	76.5%	95.14%	76.65%
INVESTING ACTIVITIES
Capital Expenditures	-$2.209M	-$1.175M	$8.871M
YoY Change	-17.88%	-59.06%	35.89%
Acquisitions
YoY Change
Other Investing Activities	$4.000K	$6.571M	$88.72M
YoY Change	-100.05%	-129.39%	-365.62%
Cash From Investing Activities	-$2.205M	$5.396M	$79.85M
YoY Change	-80.67%	-121.39%	-300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$85.66M
YoY Change			-58.33%
Cash From Financing Activities	70.86M	40.06M	181.3M
YoY Change	-711.89%	-66.01%	4.07%
NET CHANGE
Cash From Operating Activities	-72.14M	-83.11M	-281.8M
Cash From Investing Activities	-2.205M	5.396M	79.85M
Cash From Financing Activities	70.86M	40.06M	181.3M
Net Change In Cash	-3.485M	-37.66M	-20.64M
YoY Change	-94.54%	-175.25%	-18.15%
FREE CASH FLOW
Cash From Operating Activities	-$72.14M	-$83.11M	-$281.8M
Capital Expenditures	-$2.209M	-$1.175M	$8.871M
Free Cash Flow	-$69.93M	-$81.94M	-$290.7M
YoY Change	83.15%	106.29%	75.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000850261
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-36150
CY2021	dei	Entity Registrant Name EntityRegistrantName	SORRENTO THERAPEUTICS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0344842
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	4955 Directors Place
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021	dei	City Area Code CityAreaCode	858
CY2021	dei	Local Phone Number LocalPhoneNumber	203-4100
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2021	dei	Trading Symbol TradingSymbol	SRNE
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	2800000000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	342335102
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36665000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56464000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	90217000
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18715000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15506000
CY2021Q4	us-gaap	Inventory Net InventoryNet	8106000
CY2020Q4	us-gaap	Inventory Net InventoryNet	1831000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11804000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8712000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7482000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3721000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	172989000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	86234000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41325000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31861000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	85173000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42052000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	259705000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	73675000
CY2021Q4	us-gaap	Goodwill Goodwill	79525000
CY2020Q4	us-gaap	Goodwill Goodwill	43554000
CY2021Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	51271000
CY2020Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	256397000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4830000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2049000
CY2021Q4	us-gaap	Assets Assets	694818000
CY2020Q4	us-gaap	Assets Assets	535822000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	27414000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	24706000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21503000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20859000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37975000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19198000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1108000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4485000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11539000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3626000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7934000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	398000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	31980000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	23208000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	139453000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	96480000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	110627000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	92258000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2426000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6918000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	118942000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	113185000
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	35700000
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	35400000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	83431000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50301000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	124349000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	549000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1761000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2021Q4	us-gaap	Liabilities Liabilities	616689000
CY2020Q4	us-gaap	Liabilities Liabilities	395091000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	314573225
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	314573225
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	275285582
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	275285582
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	32000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	28000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1513758000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1172346000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1026000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	520000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1386604000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-958279000
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7568182
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7568182
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	49464000
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	49464000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	78748000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	165151000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-619000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	-24420000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	78129000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	140731000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	694818000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	535822000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	52904000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	39986000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	31432000
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	206922000
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	111340000
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	106879000
CY2021	srne	Research And Development In Process And Impairment Of Intangible Assets Finite Lived ResearchAndDevelopmentInProcessAndImpairmentOfIntangibleAssetsFiniteLived	24208000
CY2020	srne	Research And Development In Process And Impairment Of Intangible Assets Finite Lived ResearchAndDevelopmentInProcessAndImpairmentOfIntangibleAssetsFiniteLived	42992000
CY2019	srne	Research And Development In Process And Impairment Of Intangible Assets Finite Lived ResearchAndDevelopmentInProcessAndImpairmentOfIntangibleAssetsFiniteLived	75301000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	196856000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	116179000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	103557000
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4140000
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4053000
CY2019	us-gaap	Adjustment For Amortization AdjustmentForAmortization	3941000
CY2021	srne	Gain Loss On Contingent Consideration GainLossOnContingentConsideration	9198000
CY2020	srne	Gain Loss On Contingent Consideration GainLossOnContingentConsideration	0
CY2019	srne	Gain Loss On Contingent Consideration GainLossOnContingentConsideration	-11090000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	454355000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	284504000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	290825000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-401451000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-244518000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-259393000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-300000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	6600000
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-36792000
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-15013000
CY2020	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0
CY2019	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-6695000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-51939000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-27810000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-973000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	812000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-330000
CY2021	srne	Debt Instrument Principal Increase Adjustments DebtInstrumentPrincipalIncreaseAdjustments	28000000
CY2020	srne	Debt Instrument Principal Increase Adjustments DebtInstrumentPrincipalIncreaseAdjustments	0
CY2019	srne	Debt Instrument Principal Increase Adjustments DebtInstrumentPrincipalIncreaseAdjustments	0
CY2021	us-gaap	Interest Expense InterestExpense	10224000
CY2020	us-gaap	Interest Expense InterestExpense	20157000
CY2019	us-gaap	Interest Expense InterestExpense	35048000
CY2021	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	128000
CY2020	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	-1378000
CY2019	us-gaap	Nonoperating Gains Losses NonoperatingGainsLosses	-203000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-462528000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-310580000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-359576000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-33516000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2014000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-473000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-126000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5844000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3909000
CY2021	us-gaap	Profit Loss ProfitLoss	-429138000
CY2020	us-gaap	Profit Loss ProfitLoss	-314410000
CY2019	us-gaap	Profit Loss ProfitLoss	-363012000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-813000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-15949000
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-70944000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-428325000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-298461000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-292068000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.45
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.20
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.45
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.35
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	294774000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	229823000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132732000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	294774000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	229823000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	140514000
CY2021	us-gaap	Profit Loss ProfitLoss	-429138000
CY2020	us-gaap	Profit Loss ProfitLoss	-314410000
CY2019	us-gaap	Profit Loss ProfitLoss	-363012000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	506000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	790000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-285000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	506000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	790000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-285000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-428632000
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-313620000
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-363297000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-813000
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-15949000
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-70944000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-427819000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-297671000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-292353000
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	207500000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	492000
CY2019	srne	Stock Issued During Period Value Upon Issuance Of Warrants StockIssuedDuringPeriodValueUponIssuanceOfWarrants	8359000
CY2019	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	12648000
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	53983000
CY2019	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	484000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-285000
CY2019	us-gaap	Profit Loss ProfitLoss	-363012000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	32756000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5578000
CY2020	srne	Stock Issued During Period Value Upon Issuance Of Warrants StockIssuedDuringPeriodValueUponIssuanceOfWarrants	92773000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	317865000
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9544000
CY2020	srne	Minority Interest Changes During Period MinorityInterestChangesDuringPeriod	-55005000
CY2020	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	31419000
CY2020	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	790000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	140731000
CY2021	srne	Stock Issued During Period Value Upon Issuance Of Warrants StockIssuedDuringPeriodValueUponIssuanceOfWarrants	9050000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	201826000
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	13690000
CY2021	srne	Minority Interest Changes During Period MinorityInterestChangesDuringPeriod	0
CY2021	srne	Other Changes To Noncontrolling Interests OtherChangesToNoncontrollingInterests	651000
CY2021	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	88427000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	506000
CY2021	us-gaap	Profit Loss ProfitLoss	-429138000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	78129000
CY2021	us-gaap	Profit Loss ProfitLoss	-429138000
CY2020	us-gaap	Profit Loss ProfitLoss	-314410000
CY2019	us-gaap	Profit Loss ProfitLoss	-363012000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12462000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11007000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10989000
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	9162000
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	12897000
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	22526000
CY2021	srne	Debt Instrument Principal Increase Adjustments DebtInstrumentPrincipalIncreaseAdjustments	28000000
CY2020	srne	Debt Instrument Principal Increase Adjustments DebtInstrumentPrincipalIncreaseAdjustments	0
CY2019	srne	Debt Instrument Principal Increase Adjustments DebtInstrumentPrincipalIncreaseAdjustments	0
CY2021	srne	Payment Notes Attributed To Accreted Interest Related To Debt Discount PaymentNotesAttributedToAccretedInterestRelatedToDebtDiscount	13172000
CY2020	srne	Payment Notes Attributed To Accreted Interest Related To Debt Discount PaymentNotesAttributedToAccretedInterestRelatedToDebtDiscount	0
CY2019	srne	Payment Notes Attributed To Accreted Interest Related To Debt Discount PaymentNotesAttributedToAccretedInterestRelatedToDebtDiscount	0
CY2021	srne	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	3855000
CY2020	srne	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	3702000
CY2019	srne	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	4053000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	90188000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	31419000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	12648000
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	24208000
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	42992000
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	75301000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-6695000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-51939000
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-27810000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-300000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	6600000
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-36792000
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-15013000
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2019	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-126000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5844000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3909000
CY2021	srne	Gain Loss On Contingent Liabilities And Acquisition Consideration Payable GainLossOnContingentLiabilitiesAndAcquisitionConsiderationPayable	9198000
CY2020	srne	Gain Loss On Contingent Liabilities And Acquisition Consideration Payable GainLossOnContingentLiabilitiesAndAcquisitionConsiderationPayable	0
CY2019	srne	Gain Loss On Contingent Liabilities And Acquisition Consideration Payable GainLossOnContingentLiabilitiesAndAcquisitionConsiderationPayable	-11090000
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-35927000
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2125000
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-373000
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2957000
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1051000
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-10622000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-111000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4945000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5678000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12019000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6445000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	314000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3878000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3677000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10221000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	20747000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1188000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4061000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1024000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-362000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-945000
CY2021	srne	Deferred Rent And Other Period Increase Decrease DeferredRentAndOtherPeriodIncreaseDecrease	-3549000
CY2020	srne	Deferred Rent And Other Period Increase Decrease DeferredRentAndOtherPeriodIncreaseDecrease	-1313000
CY2019	srne	Deferred Rent And Other Period Increase Decrease DeferredRentAndOtherPeriodIncreaseDecrease	-628000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281821000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-159536000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-172996000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	124767000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8871000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6528000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11442000
CY2021	srne	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0
CY2020	srne	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0
CY2019	srne	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	17040000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	79847000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39923000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38173000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15420000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	98351000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8851000
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	49743000
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	18587000
CY2019	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	8000000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	85656000
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	205564000
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3074000
CY2021	srne	Payments Related To Share Exchange PaymentsRelatedToShareExchange	0
CY2020	srne	Payments Related To Share Exchange PaymentsRelatedToShareExchange	55000000
CY2019	srne	Payments Related To Share Exchange PaymentsRelatedToShareExchange	0
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	181332000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	174239000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78885000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-20642000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-25220000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-132284000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	843000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	915000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-277000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56464000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	80769000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	213330000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	36665000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	56464000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	80769000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1200000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	13000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1060000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	3419000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	12738000
CY2021	srne	Acquisition Costs Incurred But Not Yet Paid AcquisitionCostsIncurredButNotYetPaid	0
CY2020	srne	Acquisition Costs Incurred But Not Yet Paid AcquisitionCostsIncurredButNotYetPaid	0
CY2019	srne	Acquisition Costs Incurred But Not Yet Paid AcquisitionCostsIncurredButNotYetPaid	601000
CY2021	srne	Debt Instrument Principal Adjustments Noncash DebtInstrumentPrincipalAdjustmentsNoncash	28000000
CY2020	srne	Debt Instrument Principal Adjustments Noncash DebtInstrumentPrincipalAdjustmentsNoncash	0
CY2019	srne	Debt Instrument Principal Adjustments Noncash DebtInstrumentPrincipalAdjustmentsNoncash	0
CY2021	srne	Acea Acquisition Consideration Paid In Equity ACEAAcquisitionConsiderationPaidInEquity	42168000
CY2020	srne	Acea Acquisition Consideration Paid In Equity ACEAAcquisitionConsiderationPaidInEquity	0
CY2019	srne	Acea Acquisition Consideration Paid In Equity ACEAAcquisitionConsiderationPaidInEquity	0
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	49459000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1878000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6777000
CY2021	srne	Other Acquisitions License Agreements And Investments Consideration Paid In Equity OtherAcquisitionsLicenseAgreementsAndInvestmentsConsiderationPaidInEquity	13689000
CY2020	srne	Other Acquisitions License Agreements And Investments Consideration Paid In Equity OtherAcquisitionsLicenseAgreementsAndInvestmentsConsiderationPaidInEquity	9544000
CY2019	srne	Other Acquisitions License Agreements And Investments Consideration Paid In Equity OtherAcquisitionsLicenseAgreementsAndInvestmentsConsiderationPaidInEquity	0
CY2021	srne	Changes To Noncontrolling Interests From Increased Ownership ChangesToNoncontrollingInterestsFromIncreasedOwnership	23963000
CY2020	srne	Changes To Noncontrolling Interests From Increased Ownership ChangesToNoncontrollingInterestsFromIncreasedOwnership	0
CY2019	srne	Changes To Noncontrolling Interests From Increased Ownership ChangesToNoncontrollingInterestsFromIncreasedOwnership	0
CY2021	srne	Common Stock Received In Exchange For License CommonStockReceivedInExchangeForLicense	0
CY2020	srne	Common Stock Received In Exchange For License CommonStockReceivedInExchangeForLicense	0
CY2019	srne	Common Stock Received In Exchange For License CommonStockReceivedInExchangeForLicense	53983000
CY2021	srne	Other Loan Forgiveness OtherLoanForgiveness	7304000
CY2020	srne	Other Loan Forgiveness OtherLoanForgiveness	0
CY2019	srne	Other Loan Forgiveness OtherLoanForgiveness	0
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1253000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	600000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	849000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36665000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56464000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22521000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	0
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	58248000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36665000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56464000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	80769000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</span></p>
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-736000
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	10354000
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	947000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	0
CY2021Q4	us-gaap	Inventory Net InventoryNet	8100000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4700000
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3300000
CY2020Q4	us-gaap	Inventory Net InventoryNet	1800000
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	12037000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	947000
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	9198000
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	132284000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-300000
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	6600000
CY2019	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-36800000
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	7000000.0
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	84815000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	61874000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	43490000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30013000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41325000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31861000
CY2021	us-gaap	Depreciation Depreciation	8300000
CY2020	us-gaap	Depreciation Depreciation	7000000.0
CY2019	us-gaap	Depreciation Depreciation	7000000.0
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	3800000
CY2021Q4	us-gaap	Goodwill Goodwill	79500000
CY2021	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	35900000
CY2020	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	43600000
CY2021Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	218400000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	279210000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19505000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	259705000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	89040000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15365000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	73675000
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4100000
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	4100000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3968000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4134000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3957000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3845000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3845000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	21527000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	41276000
CY2019Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-27800000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18762920
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.97
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6621685
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.18
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1692981
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.91
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1176111
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.97
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22515513
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.19
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9952000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5200000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4100000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	3829618
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.68
CY2021	srne	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod	132540
CY2021	srne	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue	13.96
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	263182
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	9.84
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3433896
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	9.50
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	77300000
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1700000
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1400000
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	12500000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	10100000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	10000000.0
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	11225000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	9880000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	49459000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1878000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P15Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.124
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.122
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12929000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	14090000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	14196000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	13538000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	13280000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	166183000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	234216000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	139246000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	94970000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-466562000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-315516000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-362776000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3908000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-908000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-709000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-462654000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-316424000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-363485000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-19000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-68000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	38000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	72000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2375000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	58000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-37000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2413000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	111000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-78000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-80858000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-55321000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-53080000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-11999000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2730000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-12173000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	178000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-288000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-154000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-92679000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-58339000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-65407000
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-223000
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	507000
CY2019	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-94000
CY2021	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	56973000
CY2020	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	55707000
CY2019	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	65106000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-33516000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2014000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-473000
CY2021Q4	srne	Deferred Tax Assets Operating Loss And Credit Carryforwards DeferredTaxAssetsOperatingLossAndCreditCarryforwards	181428000
CY2020Q4	srne	Deferred Tax Assets Operating Loss And Credit Carryforwards DeferredTaxAssetsOperatingLossAndCreditCarryforwards	134072000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	25626000
CY2020Q4	srne	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	11726000
CY2021Q4	srne	Deferred Tax Assets Debt Related Interest DeferredTaxAssetsDebtRelatedInterest	26002000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	25456000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	33126000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	22209000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	27810000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	31140000
CY2021Q4	srne	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	19734000
CY2020Q4	srne	Deferred Tax Assets Debt Related Interest DeferredTaxAssetsDebtRelatedInterest	22448000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10516000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5359000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	15076000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	14033000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	339318000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	266443000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	261238000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	203512000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	78080000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	62931000
CY2021Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	16372000
CY2020Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	45507000
CY2021Q4	srne	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	17592000
CY2020Q4	srne	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	9146000
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	44640000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	13274000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1902000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1925000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	80506000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	69852000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2426000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6921000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-97157000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-66449000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-76332000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	56973000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	55707000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	65106000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5826000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3339000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-8904000
CY2021	srne	Effective Income Tax Rate Reconciliation Debt Discount Amount EffectiveIncomeTaxRateReconciliationDebtDiscountAmount	8954000
CY2020	srne	Effective Income Tax Rate Reconciliation Debt Discount Amount EffectiveIncomeTaxRateReconciliationDebtDiscountAmount	896000
CY2019	srne	Effective Income Tax Rate Reconciliation Debt Discount Amount EffectiveIncomeTaxRateReconciliationDebtDiscountAmount	7013000
CY2021	srne	Income Tax Reconciliation Income Tax Credits And Incentives IncomeTaxReconciliationIncomeTaxCreditsAndIncentives	9549000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-33516000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2014000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-473000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	261200000
CY2020	srne	Income Tax Reconciliation Income Tax Credits And Incentives IncomeTaxReconciliationIncomeTaxCreditsAndIncentives	3685000
CY2019	srne	Income Tax Reconciliation Income Tax Credits And Incentives IncomeTaxReconciliationIncomeTaxCreditsAndIncentives	3018000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	14472000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	4446000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	764000
CY2021	srne	Income Tax Reconciliation Acquisition Related Charges IncomeTaxReconciliationAcquisitionRelatedCharges	2711000
CY2020	srne	Income Tax Reconciliation Acquisition Related Charges IncomeTaxReconciliationAcquisitionRelatedCharges	583000
CY2019	srne	Income Tax Reconciliation Acquisition Related Charges IncomeTaxReconciliationAcquisitionRelatedCharges	18811000
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-3209000
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	7790000
CY2019	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-187000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-885000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2037000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-3726000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6397000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5336000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4352000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	258000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	133000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	257000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	7000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2442000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	928000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	734000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Acquisition UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition	36000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Acquisition UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition	0
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Acquisition UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9133000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6397000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5336000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8300000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	5600000
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	4400000
CY2021	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	0
CY2020	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	0
CY2019	us-gaap	Income Tax Examination Interest Expense IncomeTaxExaminationInterestExpense	0
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	52904000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	39986000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	31432000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	454355000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	284504000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	290825000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-401451000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-244518000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-259393000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36665000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56464000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22521000
CY2021Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	13076000
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12062000
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	13511000
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	14255000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	52904000
CY2021Q4	us-gaap	Costs And Expenses CostsAndExpenses	127685000
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	113449000
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	114061000
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	99160000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	454355000
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-144417000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-119803000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-166615000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	2510000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-428325000
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.45
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.45
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	308853000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	299276000
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	290003000
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	280604000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	294774000
CY2021Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	308853000
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	299276000
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	290003000
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	297909000
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	50884000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	284504000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	294774000
CY2020Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11505000
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11753000
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9007000
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7721000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	39986000
CY2020Q4	us-gaap	Costs And Expenses CostsAndExpenses	82028000
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	94857000
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	56735000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-71503000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-84023000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-77740000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-65195000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-298461000
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
CY2020Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	267863000
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	251211000
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	216956000
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	182609000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	229823000
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	267863000
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	257670000
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216956000
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	182609000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	229823000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-428325000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-298461000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-292068000
CY2019	us-gaap	Undistributed Earnings Loss Available To Common Shareholders Diluted UndistributedEarningsLossAvailableToCommonShareholdersDiluted	-38669000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-428325000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-298461000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-330737000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	294774000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	229823000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132732000
CY2019	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	7782000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	294774000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	229823000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	140514000
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.45
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.20
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.45
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.35

Files In Submission

Name	View Source	Status
0000950170-22-003472-index-headers.html	Edgar Link	pending
0000950170-22-003472-index.html	Edgar Link	pending
0000950170-22-003472.txt	Edgar Link	pending
0000950170-22-003472-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img176110163_0.jpg	Edgar Link	pending
img176110163_1.jpg	Edgar Link	pending
img176110163_2.jpg	Edgar Link	pending
img176110163_3.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
srne-20211231.htm	Edgar Link	pending
srne-20211231.xsd	Edgar Link	pending
srne-20211231_cal.xml	Edgar Link	unprocessable
srne-20211231_def.xml	Edgar Link	unprocessable
srne-20211231_htm.xml	Edgar Link	completed
srne-20211231_lab.xml	Edgar Link	unprocessable
srne-20211231_pre.xml	Edgar Link	unprocessable
srne-ex21_1.htm	Edgar Link	pending
srne-ex23_1.htm	Edgar Link	pending
srne-ex23_2.htm	Edgar Link	pending
srne-ex31_1.htm	Edgar Link	pending
srne-ex32_1.htm	Edgar Link	pending
srne-ex4_19.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SRNE
Sorrento Therapeutics Inc Stock $srne

2021 Q4 Form 10-K Financial Statement

#000095017022003472 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SRNE Sorrento Therapeutics Inc Stock $srne

2021 Q4 Form 10-K Financial Statement

#000095017022003472 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SRNE
Sorrento Therapeutics Inc Stock $srne